The risk factor of clinical relapse in ulcerative colitis patients with low dose 5-aminosalicylic acid as maintenance therapy: A report from the IBD registry.

Tomohiro FukudaMakoto NaganumaShinya SugimotoKosaku NankiShinta MizunoMakoto MutaguchiYoshihiro NakazatoNagamu InoueHaruhiko OgataYasushi IwaoTakanori Kanai

Published in: PloS one (2017)

A dose reduction of 5-ASA might be cautiously selected in UC patients with a history of steroid use and a shorter duration of disease remission.

Keyphrases

ulcerative colitis
low dose
risk factors
high dose
free survival
rheumatoid arthritis
systemic lupus erythematosus
mesenchymal stem cells
cell therapy